Richard Conway RichardPAConway
4 years ago
Who would have thought red cells would be so important in SLE? #ACR21 @RheumNow https://t.co/qnPuZUmEjh
TheDaoIndex KDAO2011
4 years ago
NETosing is now a verb!
Dr. Brenner: #BasicScience #YearinReview #ACR21
IFN sig driven by:
👉nucleic acid from PMNs NETosing
👉IC's containing Ab and nucleic acid
👉pDC's recog nucleic acids, produce type I IFN
risk alleles
👉Erythroid mitochondrial retention👈
@RheumNow https://t.co/dsNRj7oSBK
Janet Pope Janetbirdope
4 years ago
OK this one is cool. RNA technology used as pro inflammatory in #COVID #vaccinations but paper of RNA vector giving immunetolerance in mouse model of encephalitis. #ACRBest Yr in Review by M Brenner discussion of paper. Double edged sword ⚔️ @RheumNow #ACR21 https://t.co/8sRl351D27
Md Yuzaiful Md Yusof Yuz6Yusof
4 years ago
#ACR21 Year in Review. Caielli et al. showed in some patients with #lupus, red blood cells retained their mitochondria (Mito+ RBCs) and their frequency correlated with disease activity and blood⬆️IFN @RheumNow https://t.co/ZixgAbOWJ0 https://t.co/hkTWE4m7Ph
Eric Dein ericdeinmd
4 years ago
ADVOCATE - Avacopan: C5a inhibitor, promising new therapy for ANCA vasculitis as possible steroid sparing therapy. Non-inferior outcome of remission, sustained remission, relapse wo signif adverse effects. @rheumnow #ACR21 https://t.co/m5zexRpeS8
sheila RHEUMarampa
4 years ago
#ACR21 #YearinReview
Avacopan: The game changer for ANCA #vasculitis?🧐
🔅Remission at wk 26: Avacopan non-inferior to Pred (72.3% vs. 70.1%, p<0.001)
🔅Sustained remission at wk 56: Avacopan non-inferior to Pred (65.7% vs. 54.9%, p<0.001)
@RheumNow
https://t.co/CpPYVvRoMR https://t.co/QnsZIUQ0uu
TheDaoIndex KDAO2011
4 years ago
👉Voclosporin for SLE: rapid control of proteinuria (50% reduction over 29 days in UPCR w/o high side effects) @rheumnow #YearInReview #ACR21
Are you all starting to use this drug now? It has helped my patients; pretty well tolerated. https://t.co/zqJRsjnV4n
TheDaoIndex KDAO2011
4 years ago
Dr. K Costenbader #ACR21 #YearinReview add-ons Rx:
👉Avacopan for AAV: new oral C5a inh allowed for remission & prevention of relapse, aggressive pred taper https://t.co/39V3LLOYKZ
Eric Dein ericdeinmd
4 years ago
AURORA 1, Year in Review: Voclosporin as add-on therapy lupus nephritis. Approved in 1/2021 for active lupus nephritis, very positive data @rheumnow #ACR21 https://t.co/rudYD1OC59
Eric Dein ericdeinmd
4 years ago
Year in Review #ACR21. How do you feel about JAK inhibitor after one year of new studies and the new FDA warning? @Rheumnow
Janet Pope Janetbirdope
4 years ago
#ClinicalPearl #JAKi works in #ankylosingspondylitis (AS). Trial of #tofacitinib positive. Don’t confuse with jack ass! @YearinReview #ACR21 @RheumNow presented by Karen Costenbader https://t.co/2VvEMhiI8L
Eric Dein ericdeinmd
4 years ago
#ACR21 Year in Review: Stepped Exercise program for knee OA - decrease in pain and increase in function, without objective measures showing improvement. Time to prescribe exercise! @Rheumnow https://t.co/LrNZ3pBO9i
Bella Mehta bella_mehta
4 years ago
How to improve clinical care for knee OA? stepped exercise program helps WOMAC self reported pain outcomes in Knee OA Important RCT #ACR21 year in review by @karen_kc123 @RheumNow
@AnnalsofIM here is a paper https://t.co/RGIjBL9TuZ
Dr. John Cush RheumNow
4 years ago
#RheumPix https://t.co/gCcgE2QfIi
Cassandra Calabrese CCalabreseDO
4 years ago
Join us tomorrow at #ACR21 in the #COVID19 hub at 12p EST where I’ll be discussing outpatient management of high risk covid patients with @LCalabreseDO #mAbs @philipcrobinson @ACRheum https://t.co/LkSw48cnWw


Poster Hall